GILL DAVID N
SEC insider (Form 3/4/5 filer). CIK 0001106519. Director at Telix Pharmaceuticals Ltd (TLX) and 2 other issuers. 5 reported Form 4/5 transactions since Sep 2024; latest on Feb 17, 2026. Located in NEWPORT BEACH, CA.
Companies GILL DAVID N has filed insider reports for
- Telix Pharmaceuticals Ltd (TLX): Director
- Evolus, Inc. (EOLS): Director
- Y-mAbs Therapeutics, Inc. (YMAB): Director
GILL DAVID N
CIK: 0001106519
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (60.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (40.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Feb 17, 2026EOLS
Evolus, Inc.
AwardDirect45.6K shares- - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
DispositionDirect5.8K shares at avg. $8.60$50K - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
DispositionDirect25.1K shares- - Jun 30, 2025YMAB
Y-mAbs Therapeutics, Inc.
AwardDirect25.1K shares- - Mar 7, 2025EOLS
Evolus, Inc.
AwardDirect7.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 17, 2026 |  EOLS Evolus, Inc. | Award | 45,559 | - | $0 | Direct |
| Sep 16, 2025 |  YMAB Y-mAbs Therapeutics, Inc. | Disposition | 5,825 | $8.60 | $50,095 | Direct |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Disposition | 25,080 | - | - | Direct |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Award | 25,080 | - | - | Direct |
| Mar 7, 2025 | EOLS Evolus, Inc. | Award | 7,364 | - | - | Direct |
1-5 of 5 transactions